Summary Safety Review – Gadolinium based contrast agents – Assessing the risk of gadolinium build-up in the brain and potential brain and nervous system (neurological) side effects

Health Canada In 2016, Health Canada reviewed the risk of gadolinium build-up in the brain and the unknown potential neurological side effects because some published studies showed that gadolinium may stay in the brain when GBCAs are given repeatedly. Health Canada’s review concluded that the risk of gadolinium build-up in the brain is higher with […]

Gadolinium Retention and Breast MRI Screening: More Harm Than Good?

Francesco Sardanelli et al. The purpose of this article is to describe the risk-benefit balance of contrast-enhanced breast MRI (CE-BMRI) screening. CE-BMRI confers risk of effects associated with administration of gadolinium-based contrast agents (GBCAs), including nephrogenic systemic fibrosis and gadolinium retention. The risk-benefit balance of CE-BMRI screening is favorable for carriers of BRCA, TP53, or […]

The Debate Over Gadolinium MRI Contrast Toxicity One of the biggest concerns in radiology in recent years is the safety of gadolinium-based contrast agents (GBCAs) used in magnetic resonance imaging (MRI). Radiologists and patients began to question the safety of gadolinium a few years ago when a study came out in late 2014 showing the agent is deposited and retained in […]